<DOC>
	<DOCNO>NCT00202644</DOCNO>
	<brief_summary>Essential thrombocythaemia disorder bone marrow , cause many platelet produce . Platelets small cell carry around blood , help form blood clot . When patient many platelet , risk blood clot form unnecessarily excessive bleeding . The aim study gain additional information safety profile Anagrelide ( Xagrid ( r ) ) Hydroxyurea ( also know hydroxycarbamide ) .</brief_summary>
	<brief_title>A Study Anagrelide Hydroxyurea High-Risk Essential Thrombocythemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>Confirmed diagnosis essential thrombocythaemia high risk profile Previously untreated cytoreductive agent Females childbearing potential must negative urine pregnancy test prior enter study must agree use effective birth control duration study Diagnosis myeloproliferative disorder Any know cause secondary thrombocytosis Anticoagulant antiaggregant therapy Known suspected heart disease Left Ventricular Ejection Fraction &lt; 55 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>